Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business UpdateGlobeNewsWire • Thursday
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/27/26
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerGlobeNewsWire • 10/19/26
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 09/21/26
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/01/26
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 05/21/26
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?Zacks Investment Research • 05/19/26
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 05/14/26
Anaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/26
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of DirectorsGlobeNewsWire • 05/11/26
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 05/06/26
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceGlobeNewsWire • 05/04/26
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidencePRNewsWire • 04/28/26
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/27/26
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?Zacks Investment Research • 04/27/26